Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,959 | 12,441 | 5,005 | 8,326 | 6,886 |
| Receivables | N/A | N/A | N/A | N/A | 3,702 |
| TOTAL | $11,397 | $14,733 | $7,478 | $11,156 | $13,884 |
| Non-Current Assets | |||||
| PPE Net | 11 | 13 | 16 | 18 | 21 |
| Other Non-Current Assets | 1,039 | 1,126 | 1,264 | 334 | 334 |
| TOTAL | $1,050 | $1,139 | $1,280 | $352 | $355 |
| Total Assets | $12,447 | $15,872 | $8,757 | $11,508 | $14,239 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 491 | 490 | 1,981 | 1,462 | 893 |
| Accrued Expenses | 277 | 307 | 225 | 901 | 761 |
| TOTAL | $924 | $1,069 | $2,594 | $2,407 | $1,831 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $924 | $1,069 | $2,594 | $2,407 | $1,831 |
| Shareholders' Equity | |||||
| Common Shares | 40 | 40 | 1 | 28 | 27 |
| Retained earnings | -41,333 | -37,767 | -35,442 | -32,188 | -28,373 |
| TOTAL | $11,524 | $14,803 | $6,163 | $9,100 | $12,408 |
| Total Liabilities And Equity | $12,447 | $15,872 | $8,757 | $11,508 | $14,239 |